This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
by Zacks Equity Research
Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
ATRANegative Net Change LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
by Zacks Equity Research
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
LQDAPositive Net Change IMVTPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
RHHBYPositive Net Change MRKNegative Net Change EXELPositive Net Change NTRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
by Zacks Equity Research
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.
TGTXNegative Net Change LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs medical
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
by Zacks Equity Research
Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
LQDAPositive Net Change IMCRPositive Net Change ERNANegative Net Change INDVNegative Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
by Zacks Equity Research
ImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.
IMCRPositive Net Change IBRXPositive Net Change INDVNegative Net Change
biotechs medical
Silver Economy Investing: Why the Healthcare Giants Are in Focus
by Urmimala Biswas
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
ABTPositive Net Change LLYPositive Net Change MDTNegative Net Change ISRGNegative Net Change RMDNegative Net Change TNDMPositive Net Change
biotechs cell-therapy healthcare medical medical-devices pharmaceuticals
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
by Ekta Bagri
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
GRFSNegative Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
by Zacks Equity Research
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
REGNNegative Net Change BMYPositive Net Change MRKNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
by Zacks Equity Research
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
BMRNNegative Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs medical